Biocon Biologics, a unit of Biocon Ltd, has entered into an agreement with Voluntis for digital therapeutics for insulin. This insulia digital companion will be offered to people suffering from Type-2 diabetes. Insulia globally offers automated insulin dose recommendations enabling people with diabetes to self-manage their condition.

Interestingly, this is a new concept and Insulia is the first digital therapeutic solution with regulatory approval. Biocon Biologicals expects that pairing its product with a digital therapeutic solution will improve patient outcomes and also substantially reduce the cost of healthcare for patients. The US is one of the biggest markets for this solution.